Throughout the forecast period, the rising prevalence of cardiovascular illnesses is likely to fuel market growth. The expanding elderly population, rising frequency of cardiovascular illnesses, and sedentary lifestyle are some of the primary reasons driving the worldwide antiplatelet medicines market expansion. Growing R&D initiatives by leading market players for the development of antiplatelet medicines are projected to fuel market expansion over the forecast period. Certain antiplatelet medications' limits in effectiveness, safety, and tolerance are important challenges impeding growth in the worldwide antiplatelet pharmaceuticals market. Increased antiplatelet medication launches are likely to drive the global antiplatelet medicine market.
According to Coherent Market Insights, Global Antiplatelet Drugs Market is estimated to be valued at US$ 2,153.4 million in 2022 and is expected to exhibit a CAGR of 7.8% during the forecast period (2022-2030).
Key Competitors in the Antiplatelet Drug Industry:
AstraZeneca Plc
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. in November 2020, AstraZeneca plc launched new product Brilinta, which contained a new drug for antiplatelet namely ticagrelor had been approved by the U.S. Food and Drug Administration, to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischaemic attack (TIA).
Boehringer Ingelheim GmbH
Boehringer Ingelheim is a research-driven group of companies dedicated to researching, developing, manufacturing, and marketing pharmaceuticals that improve health and quality of life. The company is headquartered in Germany founded in 1885.
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company was founded in 1887 and is headquartered in New York, New York. In January 2022, Sanofi-aventisand Bristol-Myers Squibb Company, announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental new drug application (sNDA) for the antiplatelet agent PLAVIX(R) (clopidogrel bisulfate) to reduce the rate of death from any cause and the rate of a combined endpoint of re-infarction, stroke or death in patients with acute ST-segment elevation myocardial infarction (STEMI).